posted on 2022-12-21, 18:33authored byZhihui Yin, Zhixin Zhang, Demin Gao, Gan Luo, Tao Ma, Ying Wang, Lehui Lu, Xiaoyan Gao
Current therapeutic strategies for Alzheimer’s
disease (AD)
mainly focus on inhibition of aberrant amyloid-β peptide (Aβ)
aggregation. However, these strategies cannot repair the side symptoms
(e.g., high neuronal oxidative stress) triggered by Aβ accumulation
and thus show limited effects on suppressing Aβ-induced neuronal
apoptosis. Herein, we develop a stepwise metal–phenolic coordination
approach for the rational design of a neuroprotection enhancer, K8@Fe–Rh/Pda
NPs, in which rhein and polydopamine are effectively coupled to enhance
the treatment of AD in APPswe/PSEN1dE9 transgenic (APP/PS1) mice.
We discover that the polydopamine inhibits the aggregation of Aβ
oligomers, and rhein helps repair damage to neurons triggered by Aβ
aggregation. Based on molecular docking, we demonstrate that the polydopamine
has a strong interaction with Aβ monomers/fibrils through its
multiple recognition sites (e.g., catechol groups, imine groups, and
indolic/catecholic π-systems), thereby reducing Aβ burden.
Further investigation of the antioxidant mechanisms suggests that
K8@Fe–Rh/Pda NPs promote the mitochondrial biogenesis via activating
the sirtuin 1 (SIRT1)/peroxisome proliferator-activated receptor gamma
coactivator 1-alpha pathway. This finally inhibits neuronal apoptosis.
Moreover, an intravenous injection of these nanoparticles potently
improves the cognitive function in APP/PS1 mice without adverse effects.
Overall, our work provides a promising approach to develop advanced
nanomaterials for multi-target treatment of AD.